公开(公告)号：US20200071411A1

公开(公告)日：2020-03-05

申请号：US16684258

申请日：2019-11-14

Applicant: Hoffmann-La Roche Inc. ,  Hoffmann-La Roche Inc.

Inventor： Maria AMANN ,  Peter BRUENKER ,  Christina CLAUS ,  Claudia FERRARA KOLLER ,  Sandra GRAU-RICHARDS ,  Ralf HOSSE ,  Christian KLEIN ,  Viktor LEVITSKI ,  Pablo UMANA

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/40

Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

公开(公告)号：US20210163617A1

公开(公告)日：2021-06-03

申请号：US17017576

申请日：2020-09-10

Applicant: Hoffmann-La Roche Inc.

Inventor： Claudia FERRARA KOLLER ,  Christian KLEIN ,  Johannes SAM ,  Pablo UMANA ,  Wei XU

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to combination therapies employing a 4-1BB agonist comprising at least one antigen binding domain capable of specific binding to tumor-associated antigen in combination with specific antibodies which bind human CD20 and the use of these combination therapies for the treatment of cancer.

公开(公告)号：US20180282409A1

公开(公告)日：2018-10-04

申请号：US15763868

申请日：2016-09-30

Applicant: Hoffmann-La Roche Inc.

Inventor： Claudia FERRARA KOLLER ,  Guy GEORGES ,  Alexander HAAS ,  Hubert KETTENBERGER ,  Ekkehard MOESSNER ,  Tilman SCHLOTHAUER ,  Michael MOLHOJ ,  Laurent LARIVIERE

IPC: C07K16/28

Abstract: Herein is reported an antibody that specifically binds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.

公开(公告)号：US20180230215A1

公开(公告)日：2018-08-16

申请号：US15941519

申请日：2018-03-30

Applicant: Hoffmann-La Roche Inc.

Inventor： Thomas HOFER ,  Claudia FERRARA KOLLER ,  Ekkehard MOESSNER ,  Mi HE

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

Abstract: The present invention relates to antibodies against human CD19 (anti-human CD19 antibodies), methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.

公开(公告)号：US20250066448A1

公开(公告)日：2025-02-27

申请号：US18786187

申请日：2024-07-26

Applicant: Hoffmann-La Roche Inc.

Inventor： Claudia FERRARA KOLLER ,  Teemu Tapani JUNTTILA ,  Christian KLEIN ,  Pablo UMANA ,  Christina CLAUS

IPC: C07K14/705 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K16/32

Abstract: The invention relates to Her2 targeting 4-1BB agonists, in particular 4-1BBL trimer-containing antigen binding molecules comprising at least one antigen binding domain capable of specific binding to Her2 and their use in the treatment of cancer as well as their use in combination with T-cell activating anti-CD3 bispecific antibodies.

公开(公告)号：US20230357397A1

公开(公告)日：2023-11-09

申请号：US18166783

申请日：2023-02-09

Applicant: Hoffmann-La Roche Inc.

Inventor： Marina BACAC ,  Christina CLAUS ,  Claudia FERRARA KOLLER ,  Christian KLEIN ,  Sabine LANG ,  Viktor LEVITSKI ,  Pablo UMAÑA

IPC: C07K16/28 ,  A61P35/00 ,  C07K14/705 ,  C07K16/30 ,  C07K16/40

CPC classification number: C07K16/2809 ,  A61P35/00 ,  C07K14/70575 ,  C07K16/3007 ,  C07K16/40 ,  A61K2039/505

Abstract: The present invention relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and/or agents blocking PD-L1/PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.

公开(公告)号：US20190211113A1

公开(公告)日：2019-07-11

申请号：US16218266

申请日：2018-12-12

Applicant: Hoffmann-La Roche Inc.

Inventor： Maria AMANN ,  Peter BRUENKER ,  Christina CLAUS ,  Claudia FERRARA KOLLER ,  Sandra GRAU-RICHARDS ,  Ralf HOSSE ,  Christian KLEIN ,  Viktor LEVITSKI ,  Samuel MOSER ,  Pablo UMANA

IPC: C07K16/40 ,  C07K16/30 ,  C07K16/28

CPC classification number: C07K16/40 ,  C07K16/2875 ,  C07K16/2878 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/66 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30 ,  C07K2319/32

Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) four moities capable of specific binding to a costimulatory TNF receptor family member, (b) at least one moiety capable of specific binding to a target cell antigen, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

公开(公告)号：US20230045262A1

公开(公告)日：2023-02-09

申请号：US17819867

申请日：2022-08-15

Applicant: Hoffmann-La Roche Inc.

Inventor： Claudia FERRARA KOLLER ,  Christina CLAUS ,  Christian KLEIN ,  Pablo UMAÑA ,  Wei XU

IPC: H04N9/31 ,  G09G5/377

Abstract: The invention relates to new bispecific antigen binding molecules, comprising at least one antigen binding domain capable of specific binding to 4-1BB, at least one moiety capable of specific binding to a target cell antigen, and a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

公开(公告)号：US20220025069A1

公开(公告)日：2022-01-27

申请号：US17498515

申请日：2021-10-11

Applicant: Hoffmann-La Roche Inc.

Inventor： Christina CLAUS ,  Claudia FERRARA KOLLER ,  Christian KLEIN ,  Pablo UMAÑA

IPC: C07K16/40 ,  C07K14/475 ,  C07K16/46 ,  C07K16/32

Abstract: The invention relates to bispecific antigen binding molecule capable of bivalent binding to 4-1BB and monovalent binding to a target cell antigen comprising two lipocalin muteins capable of specific binding to 4-1BB and their use in the treatment of cancer or infectious diseases.

公开(公告)号：US20230086210A1

公开(公告)日：2023-03-23

申请号：US17811376

申请日：2022-07-08

Applicant: Hoffmann-La Roche Inc.

Inventor： Christina CLAUS ,  Claudia FERRARA KOLLER ,  Christian Klein ,  Pablo Umana

IPC: C07K16/28 ,  A61P35/00

Abstract: The invention relates to 4-1BBL trimer-containing antigen binding molecules comprising at least one antigen binding domain capable of specific binding to PD-L1 and their use in the treatment of cancer.